A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 12, 2014, Pages 1096-1101

  Xia, D Y ^a   Liu, L ^a   Hao, M W ^a   Liu, Q ^a   Chen, R A ^a   Liang, Y M ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Chronic myeloid leukemia; p15INK4B; STI571 (Gleevec, imatinib)

Indexed keywords

BCR ABL PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2B; IMATINIB; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DRUG COMBINATION; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SEQUENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MTT ASSAY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; K562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZAMIDES; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DOWN-REGULATION; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; IMATINIB MESYLATE; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; RNA, SMALL INTERFERING;

EID: 84922909267     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143734     Document Type: Article

References (27)

1. Leonetti F, Stefanachi A, Nicolotti O, Catto M, Pisani L, Cellamare S, et al. BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile. Curr Med Chem 2011; 18: 2943-2959, doi: 10.2174/0929867117 96150414.
2. Miller GD, Woessner DW, Sirch MJ, Lim CS. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML. Mol Pharm 2013; 10: 3475-3483, doi: 10.1021/mp400323c.
3. Haririan M, Kaviani S, Soleimani M, Ghaemi SR, Delalat B, Atashi A. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells. Hematology 2012; 17: 28-34, doi: 10.1179/102453311X13127324303470.
4. Zaree Mahmodabady A, Javadi HR, Kamali M, Najafi A, Hojati Z. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia. Iran Biomed J 2010; 14: 1-8.
5. Wang Z, Sampath J, Fukuda S, Pelus LM. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-ablpositive cells to STI571-induced apoptosis. Cancer Res 2005; 65: 8224-8232, doi: 10.1158/0008-5472.CAN-05-0303.
6. Niu CC, Zhao C, Zhang XL, Pan J, Zhao C, Wu WR, et al. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and gamma-catenin inhibition. Leuk Res 2013; 37: 1532-1537, doi: 10.1016/j.leukres. 2013.07.013.
7. Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, et al. Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia. J Oncol Pract 2013; 9: e212-e219, doi: 10.1200/JOP.2012.000822.
8. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007; 7: 47-55, doi: 10.1007/s10238-007-0125-z.
9. Bengio RM, Riva ME, Moiraghi B, Lanari E, Milone J, Ventriglia V, et al. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. Leuk Lymphoma 2011; 52: 1720-1726, doi: 10.3109/10428194.2011.578310.
10. Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 2009; 3: 89-101.
11. Silva KL, de Souza PS, Nestal de Moraes G, Moellmann- Coelho A, Vasconcelos FC, Maia RC. XIAP and Pglycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. Leuk Res 2013; 37: 1350- 1358, doi: 10.1016/j.leukres.2013.06.014.
12. Xia Y, Fang H, Zhang J, Du Y. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med 2013; 238: 932-942, doi: 10.1177/ 1535370213492689.
13. Oh B, Kim TY, Min HJ, Kim M, Kang MS, Huh JY, et al. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells. Anticancer Drugs 2013; 24: 20-31, doi: 10.1097/CAD. 0b013e32835a0fbd.
14. Ciarcia R, Damiano S, Montagnaro S, Pagnini U, Ruocco A, Caparrotti G, et al. Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle 2013; 12: 2839-2848, doi: 10.4161/cc.25920.
15. Guran S, Bahce M, Beyan C, Korkmaz K, Yalcin A. P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronicmyeloid leukemia. Haematologia 1998; 29: 181-193.
16. Kusy S, Larsen CJ, Roche J. p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia. Leuk Lymphoma 2004; 45: 1989-1994, doi: 10.1080/10428190410001714025.
17. Wang W, Sun BZ, Xie H, Yao LB. [Effect of tyrosine-kinase Inhibitor on p15 gene transfected K562 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 42-46.
18. Du J, Cheng B, Zhu X, Ling C. Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects. J Immunol 2011; 187: 942-950, doi: 10.4049/jimmunol.1002579.
19. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, et al. A non-ATP-competitive inhibitor of BCRABL overrides imatinib resistance. Proc Natl Acad Sci U S A 2005; 102: 1992-1997, doi: 10.1073/pnas.0408283102.
20. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602: 73-87.
21. Bies J, Sramko M, Fares J, Rosu-Myles M, Zhang S, Koller R, et al. Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood 2010; 116: 979-987, doi: 10.1182/blood-2009-08-238360.
22. Rosu-Myles M, Taylor BJ, Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol 2007; 35: 394-406, doi: 10.1016/j.exphem.2006.11.005.
23. Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, et al. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 2005; 64: 398-403.
24. Yu J, Zhou X, He X, Dai M, Zhang Q. Curcumin induces apoptosis involving bax/bcl-2 in human hepatoma SMMC- 7721 cells. Asian Pac J Cancer Prev 2011; 12: 1925-1929.
25. Belka C, Budach W. Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int J Radiat Biol 2002; 78: 643-658, doi: 10.1080/09553000210137680.
26. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489, doi: 10.1016/ S0092-8674(00)80434-1.
27. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002; 21: 8786-8803, doi: 10.1038/sj.onc.1206039.